The COVID pandemic precipitated sweeping changes in established policies and practices and emphasized the confluent dynamics of disease burdens, optimized healthcare systems, and the socio-economic influences of globalization. We now stand at the crossroads of an unprecedented global challenge which demands that researchers, regulators, policy makers, and governments address multiple dimensions that go far beyond the implications of any one healthcare scenario.
The favorable outcome of accelerated vaccine development triggered an increasingly empowered patient voice advocating for access to investigational treatments and biopharmaceutical innovation. It has also drawn attention to revisiting traditional tenets for future approvals of new drugs, and the likely longer-term considerations for medicine development paradigms.
As the healthcare and regulatory landscape evolves in Latin America, early dialogue and enhanced partnerships between biopharmaceutical industry stakeholders, and streamlined coordination among healthcare and regulatory agencies, are critical to expedite decision-making, promote increasingly sophisticated systems and data-sharing, and leverage global ecosystems and synergies in response to emerging regional challenges.
